Moderna can meet 2023 COVID vaccine forecast, unlike Pfizer: analysts

Around 20 million people need to be vaccinated with Moderna's updated COVID-19 vaccine for the company to reach US$2 billion in 2023 sales.

Moderna should hit the lower end of its sales target for this year as it only needs to tap a small portion of the private market with its COVID vaccine to reach that goal, according to industry analysts.

Around 20 million people need to be vaccinated with Moderna’s updated COVID-19 vaccine for the company to reach US$2 billion in 2023 sales from the private market, a figure four analysts told Reuters was achievable.

The company has said it expects total U.S. COVID vaccine demand to be as much as 100 million doses in the fall season.

Moderna forecast US$6 billion to US$8 billion for sales of its COVID-19 vaccine in 2023, US$2 billion to US$4 billion of which is expected to come from the commercial market. Previously signed government contracts would account for the rest.

That forecast was called into question last month, when Pfizer lowered its full-year outlook for sales of its COVID-19 shot by about US$2 billion due to lower-than-expected vaccination rates.

Moderna’s shares have fallen by some 22 per cent since its larger rival’s warning.

“It is unlikely Moderna will have a negative fall (in its sales outlook) like Pfizer because they started off much more conservative,” said Oppenheimer & Co analyst Hartaj Singh.

Jefferies analyst Michael Yee said that while the rollout of the new shots was initially slow, it seems to be picking up, citing recent data. Yee expects most of the demand to come from people aged 65 and over.